Literature DB >> 33630226

A new quantitative index in the diagnosis of Parkinson syndrome by dopamine transporter single-photon emission computed tomography.

Ryota Bando1, Hideki Otsuka2, Tamaki Otani3, Noritake Matsuda1, Shota Azane1, Yamato Kunikane1, Yoichi Otomi4, Wataru Sako5, Yuishin Izumi5, Masafumi Harada4.   

Abstract

OBJECTIVE: Dopamine transporter single-photon emission computed tomography (DAT SPECT) has been widely used to diagnose Parkinson syndrome. Using the standardized uptake value (SUV) of DAT SPECT, we propose "functional dopamine transporter volume (f-DTV)" as a new quantitative index to evaluate the three-dimensional volume of functional dopamine transporters and assess its diagnostic ability in differentiating dopaminergic neurodegenerative diseases (dNDD) from non-dNDD.
METHODS: Seventy-nine patients were enrolled (42 dNDD, 37 non-dNDD; 38 men; age 24-88 years). We analyzed seven quantitative indices. The specific binding ratio (SBR) was calculated using a program specialized for DAT SPECT (SBR_Bolt). The SUVmax, SUVpeak, and SUVmean were calculated using a quantification program for bone SPECT. SBR_SUV was calculated by dividing striatal SUVmean by the average of background SUVmean. The cutoff value of the active dopamine transporter level was examined using three methods (threshold of 40% of SUVmax, SUV 2, and SUV 3) to calculate the active dopamine transporter volume (ADV). The f-DTV was calculated by multiplying ADV and SUVmean. We assessed the correlations between SBR_Bolt and SBR_SUV, and compared the mean value of each index between the dNDD and non-dNDD groups. The abilities of SBR_Bolt, SBR_SUV, SUVmax, SUVpeak, SUVmean, ADV, and f-DTV in differentiating dNDD from non-dNDD were determined by the area under the receiver operating curve (AUC) generated by the receiver operating characteristics analysis.
RESULTS: The SBR_Bolt and SBR_SUV highly correlated with each other (r = 0.71). The cutoff value of the active dopamine transporter level was determined as SUV 3. All seven quantitative indices showed lower values in the dNDD group than in the non-dNDD group, and the difference between the two groups was statistically significant (p < 0.05). Sensitivity, specificity, and AUC of f-DTV were slightly lower than those of SBR_Bolt (71%, 79%, and 0.81, respectively, for f-DTV, and 81%, 84%, 0.88, respectively, for SBR_Bolt). The difference in AUC between f-DTV and SBR_Bolt was not statistically significant.
CONCLUSIONS: This study demonstrates the utility of f-DTV as a novel quantitative index for evaluating the three-dimensional volume of functional dopamine transporters, and that f-DTV has almost the same diagnostic ability to differentiate dNDD from non-dNDD using DAT SPECT.

Entities:  

Keywords:  Active dopamine transporter volume; Dopamine transporter SPECT; Functional dopamine transporter volume; Parkinson syndrome; SUV

Year:  2021        PMID: 33630226     DOI: 10.1007/s12149-021-01592-w

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  22 in total

Review 1.  Molecular imaging of the dopamine transporter.

Authors:  Andrea Varrone; Christer Halldin
Journal:  J Nucl Med       Date:  2010-08-18       Impact factor: 10.057

2.  Semiquantitative analysis using standardized uptake value in 123I-FP-CIT SPECT/CT.

Authors:  Akira Toriihara; Hiromitsu Daisaki; Akihiro Yamaguchi; Makoto Kobayashi; Shogo Furukawa; Katsuya Yoshida; Jun Isogai; Ukihide Tateishi
Journal:  Clin Imaging       Date:  2018-06-15       Impact factor: 1.605

3.  Comparison between visual assessment of dopaminergic degeneration pattern and semi-quantitative ratio calculations in patients with Parkinson's disease and Atypical Parkinsonian syndromes using DaTSCAN® SPECT.

Authors:  Anette Davidsson; Charalampos Georgiopoulos; Nil Dizdar; Göran Granerus; Helene Zachrisson
Journal:  Ann Nucl Med       Date:  2014-07-06       Impact factor: 2.668

4.  Visual versus automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism.

Authors:  Elina Mäkinen; Juho Joutsa; Jarkko Johansson; Maija Mäki; Marko Seppänen; Valtteri Kaasinen
Journal:  J Neural Transm (Vienna)       Date:  2016-06-20       Impact factor: 3.575

5.  Metabolic activity by 18F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC.

Authors:  Kyoichi Kaira; Tetsuya Higuchi; Ichiro Naruse; Yukiko Arisaka; Azusa Tokue; Bolag Altan; Satoshi Suda; Akira Mogi; Kimihiro Shimizu; Noriaki Sunaga; Takeshi Hisada; Shigehisa Kitano; Hideru Obinata; Takehiko Yokobori; Keita Mori; Masahiko Nishiyama; Yoshihito Tsushima; Takayuki Asao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-21       Impact factor: 9.236

Review 6.  The role of DAT-SPECT in movement disorders.

Authors:  G Kägi; K P Bhatia; E Tolosa
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-01       Impact factor: 10.154

7.  Added Value of Combined Semi-Quantitative and Visual [123I]FP-CIT SPECT Analyses for the Diagnosis of Dementia With Lewy Bodies.

Authors:  Nicolas Nicastro; Valentina Garibotto; Gilles Allali; Frederic Assal; Pierre R Burkhard
Journal:  Clin Nucl Med       Date:  2017-02       Impact factor: 7.794

8.  Combined visual and semi-quantitative assessment of 123I-FP-CIT SPECT for the diagnosis of dopaminergic neurodegenerative diseases.

Authors:  Jun Ueda; Hajime Yoshimura; Keiji Shimizu; Megumu Hino; Nobuo Kohara
Journal:  Neurol Sci       Date:  2017-04-07       Impact factor: 3.307

9.  The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes.

Authors:  Naoto Uyama; Hideki Otsuka; Takayoshi Shinya; Yoichi Otomi; Masafumi Harada; Wataru Sako; Yuishin Izumi; Ryuji Kaji; Yuya Watanabe; Satoru Takashi; Yamato Kunikane
Journal:  Nucl Med Commun       Date:  2017-06       Impact factor: 1.690

10.  Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer.

Authors:  Ichiei Kuji; Tomohiko Yamane; Akira Seto; Yota Yasumizu; Suguru Shirotake; Masafumi Oyama
Journal:  Eur J Hybrid Imaging       Date:  2017-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.